- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01868360
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Subconjunctival Aflibercept Injection for Corneal Neovascularization
The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. The current standard of care to prevent graft rejection includes use of topical steroids and medicines that suppress the immune system. These medicines do not address corneal neovascularization. The purpose of the study is to establish the safety and potential efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron) injection in inducing regression of blood vessels growing into the cornea and promoting graft survival.
This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Corneal neovascularization is a sight threatening condition and is also a well recognized risk factor for corneal graft failure. Current standard of care to prevent graft rejection includes use of topical steroids and immunosuppressants. These do not address corneal neovascularization. The cornea is kept in its avascular state by a complex interaction of signal proteins and host receptors, with a vital role played by the soluble VEGF-receptor 1. In any condition of chronic corneal inflammation or hypoxia, the balance may tip in favour of pro-angiogenic factors, and neovascularization will ensue. Early and limited studies have examined the effect of subconjunctival or intracorneal administration of monoclonal antibodies to VEGF (bevacizumab, ranibizumab) in combating corneal neovascularization. Most report subtotal or temporary regression. The development of aflibercept (also known as VEGF Trap-Eye) offers new hope of more effectively combating the problem. In this study, research will be conducted to investigate and assess safety of subconjunctival aflibercept injection in patients with corneal neovascularization undergoing corneal transplantation.
This is a phase 1, prospective, randomized, open label clinical trial that will enroll 10 corneal transplant patients with corneal neovascularization in one or more quadrants crossing more than 0.5 mm over the limbus at the time of corneal transplantation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- John A. Moran Eye Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient must meet the following criteria to be eligible for inclusion in the study:
- Candidates for corneal transplantation (only one eye per patient would be enrolled)
- Patients with corneal neovascularization in one or more quadrants crossing more than 1.0 mm over the limbus at time of enrollment in the study
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
- Age 18 or over
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
- Patients receiving antiangiogenic anti-VEGF medication either systemically or intravitreally for other pathology or have received these drugs within 3 months of study enrollment
- Patients with active corneal infection requiring additional treatment modalities
- Patients receiving coumadin with INR >2.0, other anti-thrombotic agents (e.g., aspirin, Plavix) permitted at discretion of investigator
- History of cerebrovascular accident or myocardial infarction within 6 months prior to study enrollment
- Uncontrolled blood pressure- defined as SBP>160 mmHg or DBP >95mmHg while patient is sitting
- Pregnant or breast-feeding women
- Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A subconjunctival aflibercept
Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation. Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period. |
subconjunctival aflibercept injection
Other Names:
|
Placebo Comparator: Group B: Standard of care only
Patients will receive standard of care (steroids and cyclosporine) treatment only.
|
Patients will receive standard of care (steroids and cyclosporine) treatment only.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety defined by incidence and severity of adverse events at week 28
Time Frame: Week 28
|
The primary endpoint in the study is safety as defined by incidence and severity of adverse events in patients with corneal neovascularization undergoing corneal transplant.
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for immunosuppression
Time Frame: week 52
|
need for immunosuppression at week 52 in both treatment groups
|
week 52
|
neovascularization regression
Time Frame: at time of transplant
|
Ability of subconjunctival aflibercept injection to regress neovascularization at time of transplant and promote graft survival after corneal transplantation
|
at time of transplant
|
Need for immunosuppression
Time Frame: Week 28
|
Need for immunosuppression at week 28 in both treatment groups
|
Week 28
|
Effect on corneal infections
Time Frame: Through week 28
|
Effect on corneal infections or other side effects through week 28 in both treatment groups
|
Through week 28
|
Change in visual acuity
Time Frame: Week 28
|
Change in ETDRS visual acuity from baseline at week 28 in both treatment groups
|
Week 28
|
Mean number of injections
Time Frame: Week 28
|
Mean number of injections performed per patient through week 28 in patients receiving subconjunctival aflibercept injections
|
Week 28
|
Rescue therapy
Time Frame: Week 28
|
Need for rescue treatment in the standard of care group through week 28
|
Week 28
|
neovascularization regression
Time Frame: at 28 weeks after transplant
|
Ability of subconjunctival aflibercept injection to regress neovascularization (at 28 weeks after transplant) and promote graft survival after corneal transplantation
|
at 28 weeks after transplant
|
neovascularization regression
Time Frame: at 52 weeks after transplantation
|
Ability of subconjunctival aflibercept injection to regress neovascularization at 52 weeks after transplant and promote graft survival after corneal transplantation
|
at 52 weeks after transplantation
|
Effect on corneal infections
Time Frame: Through week 52
|
Effect on corneal infections or other side effects through week 52 in both treatment groups.
|
Through week 52
|
Change in visual acuity
Time Frame: Week 52
|
Change in ETDRS visual acuity from baseline at week 52 in both treatment groups
|
Week 52
|
Mean number of injections
Time Frame: Week 52
|
Mean number of injections performed per patient through week 52 in patients receiving subconjunctival aflibercept injections
|
Week 52
|
Rescue therapy
Time Frame: Week 52
|
Need for rescue treatment in the standard of care group through week 52
|
Week 52
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Balamurali Ambati, M.D., Ph.D., M.B.A., University of Utah
Publications and helpful links
General Publications
- Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007.
- Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001 Aug;12(4):242-9. doi: 10.1097/00055735-200108000-00002.
- The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992 Oct;110(10):1392-403.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMB65110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Neovascularization
-
Reza Dana, MDUnited States Department of Defense; New York Presbyterian Hospital; Bascom Palmer...CompletedCorneal Neovascularization | Corneal Graft FailureUnited States
-
Reza Dana, MDCompletedCorneal Neovascularization | Corneal Graft FailureUnited States
-
Medical University of ViennaCompletedKeratoconus | Corneal NeovascularisationAustria
-
University of NottinghamUnknownCorneal Neovascularisation
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingCorneal NeovascularizationChina
-
Chengdu Kanghong Biotech Co., Ltd.UnknownCorneal NeovascularizationChina
-
Chonnam National University HospitalCompletedCorneal Neovascularization
-
Asociación para Evitar la Ceguera en MéxicoNational Council of Science and Technology, Mexico; Universidad Nacional Autonoma...CompletedCorneal NeovascularizationMexico
-
Yonsei UniversityWithdrawn
-
Reza Dana, MDCompletedCorneal NeovascularizationUnited States
Clinical Trials on Subconjunctival aflibercept
-
Singapore Eye Research InstituteCompletedOcular Hypertension
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
Red de Terapia CelularFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia and other collaboratorsCompleted
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
-
Instituto de Olhos de GoianiaCompleted